Blue Cross Blue Shield of Massachusetts says it will soon stop covering popular drugs for weight loss, like Ozempic.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Massachusetts' largest commercial health insurer is rolling back its coverage of GLP-1 drugs like Ozempic and Wegovy for ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6% and also help people lose up to 16 ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent ...

Known as GLP-1-based drugs, this medication class could have the medical and societal impact of blockbusters like Viagra, Lipitor, and Prozac. Like them, these weight-loss drugs have the potential ...

The bold move has been accompanied by a full-page ad in the Wall Street Journal explaining its reasoning, and claiming that the prices of GLP-1 drugs for weight loss are five times too high and ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

As GLP-1 weight loss drugs have surged in popularity, the Food and Drug Administration has ordered medical professionals offering compounded versions of these drugs to stop services on April 22.